Abstract
360MO Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have